Washington Report: Safety First - Pharmaceutical Executive

ADVERTISEMENT

Washington Report: Safety First
FDA seeks to regain public trust by making drug-safety information more transparent—and to head off more stringent legislation in the process. wave of collaborations between industry, non-profits, and government seeks affordable treatments for neglected diseases around the world.


Pharmaceutical Executive



Jill Wechsler
THE INSTITUTE OF MEDICINE (IOM) issued a report last September urging the Food and Drug Administration (FDA) to change the way it operates, in order to achieve better balance in the agency's assessment of the risks and benefits of drugs. FDA commissioner Andrew von Eschenbach responded a few weeks ago with a detailed safety program. FDA plans to develop safety report cards on important new drugs, create an online drug-safety newsletter, and improve the agency's ability to detect safety signals by accessing more health system databases. The leaders of the Center for Drug Evaluation and Research (CDER) also promise to address the tension between pre- and post-approval staffs by orchestrating a "true culture change" that gives safety analysts more authority over regulatory decisions.

The unstated goal of the program is to soften legislation that would require more significant organizational changes and impose new mandates on manufacturers and regulators alike. Senators Charles Grassley (R-IA) and Chris Dodd (D-CT) continue to back a bill establishing a separate drug-safety office at FDA. And Senators Edward Kennedy (D-MA) and Mike Enzi (R-WY) have offered a bill requiring risk-mitigation strategies for all new drugs and mandatory clinical-trial registration.


Fees for Safety
The FDA announcement covered activities the agency can implement on its own, as long as it gains sufficient funding. The plan does not address IOM proposals requiring congressional action, such as giving the agency authority to levy fines on companies that fail to complete promised post-approval studies. The agency also did not respond to recommendations for special warning symbols on high-risk products and limits on DTC advertising of newly approved drugs, an issue that is gaining attention in Washington. But it seems clear that if FDA and industry want Congress to reauthorize the Prescription Drug User Fee Act (PDUFA) by fall, they probably will have to accept some new legislative requirements designed to ensure the safety of medicines.

More Assessment

The FDA plan addresses IOM's recommendations on assessment and communication of risk information. But some of its proposals fall short of what critics had demanded. For example, IOM had suggested a scheduled reevaluation of new drugs a year or so after launch, as would occur under a conditional-approval system. The pilot plan to issue report cards on newly approved drugs responds to that demand—but not completely. FDA proposes to evaluate adverse-event reports, additional clinical studies, and epidemiologic information, starting with two or three new molecular entities (NMEs). These just now are being selected for the pilot, so the first assessments won't appear for at least 18 months. But the reports will be made public, and the program could be extended to all new drugs if it seems to provide a more complete picture of safety issues throughout the product lifecycle.

There also has been a clamor for FDA to publicly disclose more drug safety information from post-approval studies and adverse-event reports. The industry, arguing that sponsors and regulators should have the opportunity to evaluate safety information before publicizing it, has opposed the proposal. FDA has offered a compromise: It dropped its earlier proposal for a "Drug Watch" Web site and proposes to launch an online newsletter with summaries of FDA post-marketing drug reviews, emerging safety issues, and information on newly approved products. The summaries will be cleansed of confidential commercial information.

The Kennedy-Enzi bill would require all new-drug applications (NDAs) to include risk management plans (RiskMAPS), and the IOM report urged further evaluation of such approaches. FDA says it will review one or two RiskMAPS every year and post the results to help assess how effectively these programs address serious safety issues.


ADVERTISEMENT

blog comments powered by Disqus
UPCOMING CONFERENCES

Serialization Summit
San Diego, CA
Feb. 27-28, 2014



Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014



ClinTech 2014
Cambridge, MA
Mar. 11-13 2014


Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Source: Pharmaceutical Executive,
Click here